BioVex
ExitedFDA-approved virus engineered to specifically kill cancer cells
BioVex has raised €76M across 3 funding rounds from 13 investors, most recently a Series D+ round in Nov 2009. Based in Oxton, UK; founded 1999; active in Healthtech. Acquired by Amgen in 2010. Data as of 28 Oct 2026.
Total raised
€76M
€76,240,211
Funding rounds
3
Investors
13
distinct backers
Active since
2003-10
latest 2009-11
Funding by year
EUR raised per yearBioVex — funding by year — interactive chart.
Data table
| BioVex — funding by year | |
|---|---|
| 2003 | €24M |
| 2009 | €52M |
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2009-11-01 | Series D+ | €20M | Morningside Ventures,Sectoral Asset Management,Ventech,Ysios Capital | View deal → |
| 2009-03-01 | Series D+ | €32M | Innoven Partners,New Science Ventures,Omnes Capital,Scottish Equity Partners | View deal → |
| 2003-10-01 | Series C | €24M | ABN AMRO,Avalon Ventures,CLSA,LDC,Temasek | View deal → |
Exit
Type
acquisition
Date
Jan 2011
Value
€909M
Acquiror
Amgen (United States Thousand Oaks)